Epidemiology, impact, management, and cost of Paget's disease of bone in France
| Autor: | Alain Saraux, Anne-Marie Vigneron, Viviane Mimaud, Antoine Lafuma, Catherine Brun-Strang |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics Total cost Population Disease Cost of Illness Rheumatology Quality of life Epidemiology Prevalence Humans Medicine Prospective Studies Practice Patterns Physicians' Sex Distribution education Aged Retrospective Studies education.field_of_study Bone Density Conservation Agents Diphosphonates business.industry Type 2 Diabetes Mellitus Osteitis Deformans medicine.disease Hospitalization Cross-Sectional Studies Paget's disease of bone Radiological weapon Quality of Life Physical therapy Female France business |
| Zdroj: | Joint Bone Spine. 74:90-95 |
| ISSN: | 1297-319X |
| DOI: | 10.1016/j.jbspin.2006.10.002 |
| Popis: | Objectives To evaluate the epidemiology, quality-of-life (QoL) impact, management, and cost of Paget's disease of bone. Methods Retrospective and prospective data were collected in a representative cross-section of office-based and hospital-based rheumatologists in France, in early 2005. Each rheumatologist included consecutive outpatients with Paget's disease seen over a 2-month period. For each patient, a medical questionnaire and the 36-item Short-Form self-questionnaire (SF-36) evaluating health-related quality of life were completed. A descriptive analysis of the patient population was conducted. Medical costs over the last 12 months were estimated. Results Four hundred and forty-six medical questionnaires and 387 SF-36 questionnaires were available. Mean age was 74 years, and 58.3% of patients were male. The diagnosis was fortuitous (usually radiological) in 39.2% of cases. Complications occurred in 40% of cases; 97.8% of complications involved the joints. Bisphosphonate therapy was used in nearly 84% of patients. The SF-36 scores were significantly decreased compared to the general population, in both males and females. Total cost of management was less than one-third the cost of managing type 2 diabetes mellitus. Conclusion The results confirm the well-established characteristics of Paget's disease. Bisphosphonate therapy was widely used. Quality of life was significantly altered. The cost of management was moderate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect